At World Sleep 2025, Robson Capasso, MD, of Stanford University in California, challenged the field's reliance on the apnea-hypopnea index (AHI) as the primary measure of treatment success in ...
Two randomized controlled trials show reduction in AHI; significant improvements seen in all secondary end points. (HealthDay News) — Tirzepatide reduces the apnea-hypopnea index (AHI) among ...
Sleep apnea affects as many as 80 million in the U.S. Now Apnimed, the $400 million company behind the first ever pill to ...
Mirroring results reported in a phase IIb study, Apnimed Inc.’s first of two pivotal trials testing AD-109 as an oral therapy in obstructive sleep apnea hit primary and secondary endpoints. Should ...
Findings showed a significantly greater proportion of patients treated with AD109 had an improvement (reduction) in AHI score compared with those who received placebo. Topline data were announced from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback